Clinical Scorecard: Evaluating the Predictive Significance of NRI, NLR, PLR, and LMR for Treatment Outcomes and Prognosis in Advanced Rectal Cancer Patients Undergoing PD-1/PD-L1 Immunotherapy

At a Glance

Key Highlights

• Retrospective analysis of 172 advanced rectal cancer patients
• Optimal cut-off values: NLR 2.50, PLR 142.23, LMR 3.92, NRI 50.45
• High NLR and PLR associated with shorter median progression-free survival (PFS) and overall survival (OS)
• NLR≥2.50 identified as an independent biomarker for poor efficacy and prognosis
• Correlation between nutritional and inflammatory indicators and immunotherapy outcomes

Guideline-Based Recommendations

Diagnosis

• Histopathological confirmation of rectal adenocarcinoma
• Staging according to AJCC Rectal Cancer Staging System

Management

• Consider PD-1/PD-L1 inhibitors for eligible patients
• Evaluate nutritional and inflammatory biomarkers for treatment planning

Monitoring & Follow-up

• Regular assessment of NRI, NLR, PLR, and LMR during treatment

Risks

• High NLR and PLR are independent risk factors for shortened PFS and OS

Patient & Prescribing Data

Patients aged > 18 years with advanced rectal cancer, staged III to IV

Patients received at least 2 cycles of PD-1/PD-L1 inhibitor therapy, with or without combination therapies

Clinical Best Practices

• Utilize NRI, NLR, PLR, and LMR as predictive biomarkers for immunotherapy efficacy
• Incorporate multidisciplinary team assessments for treatment eligibility
• Monitor for potential complications and treatment responses regularly

Related Resources & Content

• American Joint Committee on Cancer (AJCC) Rectal Cancer Staging System